Author:
Lopes Snehal S.,Pericot-Valverde Irene,Lum Paula J.,Taylor Lynn E.,Mehta Shruti H.,Tsui Judith I.,Feinberg Judith,Kim Arthur Y.,Norton Brianna L.,Page Kimberly,Murray-Krezan Cristina,Anderson Jessica,Karasz Alison,Arnsten Julia,Moschella Phillip,Heo Moonseong,Litwin Alain H.
Abstract
Abstract
Background
Self-reported adherence to direct-acting antivirals (DAAs) to treat hepatitis C virus (HCV) among persons who inject drugs (PWID) is often an overreport of objectively measured adherence. The association of such overreporting with sustained virologic response (SVR) is understudied. This study among PWID aimed to determine a threshold of overreporting adherence that optimally predicts lower SVR rates, and to explore correlates of the optimal overreporting threshold.
Methods
This study analyzed per-protocol data of participants with adherence data (N = 493) from the HERO (Hepatitis C Real Options) study. Self-reported and objective adherence to a 12-week DAA regimen were measured using visual analogue scales and electronic blister packs, respectively. The difference (Δ) between self-reported and objectively measured adherence was calculated. We used the Youden index based on receiver operating characteristic (ROC) curve analysis to identify an optimal threshold of overreporting for predicting lower SVR rates. Factors associated with the optimal threshold of overreporting were identified by comparing baseline characteristics between participants at/above versus those below the threshold.
Results
The self-reported, objective, and Δ adherence averages were 95.1% (SD = 8.9), 75.9% (SD = 16.3), and 19.2% (SD = 15.2), respectively. The ≥ 25% overreporting threshold was determined to be optimal. The SVR rate was lower for ≥ 25% vs. < 25% overreporting (86.7% vs. 95.8%, p <.001). The factors associated with ≥ 25% Δ adherence were unemployment; higher number of days and times/day of injecting drugs; higher proportion of positive urine drug screening for amphetamine, methamphetamine, and oxycodone, and negative urine screening for THC (tetrahydrocannabinol)/cannabis.
Conclusions
Self-reported DAA adherence was significantly greater than objectively measured adherence among PWID by 19.2%. Having ≥ 25% overreported adherence was associated with optimal prediction of lower SVR rates. PWID with risk factors for high overreporting may need to be more intensively managed to promote actual adherence.
Funder
Patient-Centered Outcomes Research Institute
Gilead Sciences
Publisher
Springer Science and Business Media LLC
Reference36 articles.
1. Bruggmann P, Grebely J. Prevention, treatment and care of hepatitis C virus infection among people who inject drugs. Int J Drug Policy. 2015;26:22–S6. 014. PubMed PMID: WOS:000425828900005.
2. Centers for Disease Control and Prevention. Viral Hepatitis Surveillance Report– United States, 2020 2022, September [cited 2023 6/27/2023]. Available from: https://www.cdc.gov/hepatitis/statistics/2020surveillance/hepatitis-c.htm.
3. Degenhardt L, Peacock A, Colledge S, Leung J, Grebely J, Vickerman P, et al. Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review. Lancet Global Health. 2017;5(12):E1192–E207. https://doi.org/10.1016/S2214-109X(17)30375-3. PubMed PMID: WOS:000414869500020.
4. Macias J, Morano L, Tellez F, Granados R, Rivero-Juarez A, Palacios R, et al. Response to direct-acting antiviral therapy among ongoing drug users and people receiving opioid substitution therapy. J Hepatol. 2019;71(1):45–51..018. PubMed PMID: WOS:000471646900008.
5. Litwin AH, Lum PJ, Taylor LE, Mehta SH, Tsui JI, Feinberg J, et al. Patient-centred models of hepatitis C treatment for people who inject drugs: a multicentre, pragmatic randomised trial. Lancet Gastroenterol Hepatol. 2022;7(12):1112–27.